Before his Clovis tenure, Patrick Mahaffy spearheaded Pharmion, leading it from 2000 until its 2008 acquisition by Celgene, which later morphed into Bristol Myers Squibb. His leadership prowess also touched Nexstar Pharmaceuticals between 1992 and 1998 before integrating with Gilead Sciences. Under his vision, both enterprises introduced groundbreaking oncology medicines in the European and American markets. An accolade worth underscoring is the enduring impact of the drugs ushered into the market during his tenure. They remain at the forefront as primary therapeutic guidelines or integral components in treatment regimes. Mahaffy's foray into the corporate world commenced at Warburg Pincus, where he honed his skills as an investment banker from 1986 until 1992.